---
title: "Jiangsu Recbio’s Novel HPV Vaccine Trial Approved in China"
date: "2025-02-12 21:09:12"
summary: "Maximize Your Portfolio with Data Driven Insights:Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions. Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart PortfolioJiangsu Recbio Technology Co., Ltd. Class..."
categories:
  - "tipranks_announcements"
lang:
  - "en"
translations:
  - "en"
tags:
  - "tipranks_announcements"
menu: ""
thumbnail: "https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_1917115745-750x406.jpg"
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

### Maximize Your Portfolio with Data Driven Insights:

* Leverage the power of [TipRanks' Smart Score](https://www.tipranks.com/screener/top-smart-score-stocks), a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
* Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with  [Your Smart Portfolio](https://www.tipranks.com/smart-portfolio/holdings)

Jiangsu Recbio Technology Co., Ltd. Class H ( [(HK:2179)](https://www.tipranks.com/stocks/hk:2179) ) just unveiled an update.

Jiangsu Recbio Technology Co., Ltd. announced the acceptance of its application for a clinical trial of its new HPV 9-valent vaccine, REC604c, by the National Medical Products Administration in China. The REC604c vaccine, enhanced with a novel adjuvant developed in-house, seeks to reduce vaccination doses while boosting immunogenicity and cross-protection. This development targets the male market, acknowledging the global trend of including adolescent males in HPV vaccination programs. The potential market in China is significant, with over 300 million eligible males, but success is not guaranteed.

**More about Jiangsu Recbio Technology Co., Ltd. Class H**

Jiangsu Recbio Technology Co., Ltd. is a biotechnology company based in China, focusing on the development of innovative vaccines. The company specializes in recombinant vaccines, targeting markets for various age groups and genders.

**YTD Price Performance:** -8.63%

**Average Trading Volume:** 31,379

**Technical Sentiment Consensus Rating:** Buy

**Current Market Cap:** HK$3.96B

Find detailed analytics on 2179 stock on [TipRanks’ Stock Analysis page](https://www.tipranks.com/stocks/hk:2179/stock-analysis).

Trending Articles:
------------------

* [SUI Lawsuit Alert! Class Action Against Sun Communities, Inc.](https://www.tipranks.com/news/sui-lawsuit-alert-class-action-against-sun-communities-inc)
* [Meta Stock Alert! Wins New Street-High Price Target from Tigress Financial](https://www.tipranks.com/news/meta-stock-alert-wins-new-street-high-price-target-from-tigress-financial)
* [Buffett’s Berkshire Ups Occidental Stake to 28.3% by Buying More Shares](https://www.tipranks.com/news/buffetts-berkshire-ups-occidental-stake-to-28-3-by-buying-more-shares)

[tipranks_announcements](https://www.tipranks.com/news/company-announcements/jiangsu-recbios-novel-hpv-vaccine-trial-approved-in-china)
